MedPath

Physiopathology of Neuromuscular Function Related to Fatigue in Chronic Renal Disease

Not Applicable
Conditions
Chronic Kidney Disease Stage 3B
Chronic Kidney Disease Stage 5
Fatigue
Chronic Kidney Disease stage4
Interventions
Other: Handgrip fatigability test
Other: Questionnaires
Registration Number
NCT04330807
Lead Sponsor
Centre Hospitalier le Mans
Brief Summary

Chronic Kidney Disease (CKD) induces many metabolic troubles especially for the advanced CKD (stage 3b-5) patients and their prevalence and importance grow with the deterioration of the glomerular filtration rate (GFR). Among them, muscle wasting is common and multifactorial, partially explained by an imbalance between protein catabolism and synthesis. Muscular strength is also affected beyond the reduction of the lean body mass, resulting in profound fatigue.

The present study seeks to quantify the prevalence of low muscular strength production (dynapenia) in a cohort of elderly patients with advanced CKD, through a maximal voluntary contraction (MVC) handgrip test compared to control data available in the literature, matched in term of age and sex. It also aims to investigate the link between the reported fatigue (subjective) and the evolution of the MVC, called critical force (fcrit) during a fatiguing task (objective fatigability).

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
220
Inclusion Criteria
  • Adults, aged 60 and over
  • Social security coverage
  • Signed informed consent
  • For patient with Chronic Kidney Disease, estimated glomerular filtration rate (eGFR) less than 45ml/min/1.73m2 (Stage 3b) for at least 3 months
  • For patient with Chronic Kidney Disease, stable clinical condition (i.e., Creatinine increased by a maximum of 25% in the previous 3 months)
  • For control group, 1:1 recruitment with case matching with CDK patients on gender (i.e., male and female) and the presence of diabètes (i.e., presence and absence)
  • For control group, blood test with control of renal function available and dated less than 6 months: with eGFR > 60ml/min/1.73m2 (and control of glucose or glycated hemoglobin for diabetic controls)
Exclusion Criteria
  • Pregnant women
  • Under guardianship or minor
  • Neuromuscular disease
  • Dementia
  • Upper limbs history of surgery or pathologies preventing from fitting EMG electrodes or measuring handgrip force
  • Life expectancy of less than 3 months estimated by medical judgment
  • Programed hospitalization in the previous 3 months
  • Participation to another interventional clinical trial
  • Acute kidney disease
  • On dialysis or expected start of dialysis within next 3 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CONTROL GROUPQuestionnairesPatients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
CONTROL GROUPHandgrip fatigability testPatients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
Patient with chronic kidney diseaseHandgrip fatigability testPatients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
Patient with chronic kidney diseaseQuestionnairesPatients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
Primary Outcome Measures
NameTimeMethod
DYNAPENIA1 day

The main outcome of the study is to defined the prevalence of dynapenia for advanced CKD elderly patients. Dynapenia will be established when the mean of the first three MVC of the protocol is lower compared to the reference values appaired for age and sex. For reference values of elderly, please see Ramírez-Vélez et al., (2019).

Secondary Outcome Measures
NameTimeMethod
Objective fatigue1 day

The nmF is an indicator of the objective fatigue, it is identified by measuring the Fcrit during the fatigability period of the protocol (Figure 1). The value of Fcrit is the asymptote of the MVC curve plotted. This value is calculated for each individual.

EMG signal1 day

To analyze the amplitude of the EMG signal recorded, it will be rectified with the Root Mean Square (RMS) method. Frequency analysis will be performed with the Fast Fourier Transform (FFT).

Subjective fatigue1 day

The symptom of fatigue will be assessed with two questionnaires, the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and the Multidimensional Fatigue Inventory (MFI-20). FACIT-F is a validated questionnaire in French language (Kwakkenbos et al., 2014), slightly short, including 13 pragmatically and simple affirmations (e.g., I am too tired to eat) with Likert scale (0: "Not at all" to 4: "enormously"). The questionnaire depicted 4 dimensions (i.e., General fatigue, mental fatigue, reduced activities, motivation) and the final score ranges from 0 to 52, with an elevated score depicted a low fatigue. MFI-20 is a validated questionnaire in French language (Gentile et al., 2003) focused about fatigue. It is built with a balance between positive trend questions (e.g., Physically I feel I am in an excellent condition) and negative trend question (e.g., Physically I feel only able to do a little). An elevated score depicted a higher fatigue.

Trial Locations

Locations (1)

Centre Hospitalier Du Mans

🇫🇷

Le Mans, France

© Copyright 2025. All Rights Reserved by MedPath